Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18466056 | 0.88 | BACE1 (0.46) | BACE1BACE2PTGS1PTGS2PIM1 | |
| SCHEMBL25042151 | 0.82 | ROCK2 (0.40) | BACE1BACE2PTGS1PTGS2CNR2 | |
| SCHEMBL17070966 | 0.82 | NR1H4 (0.44) | BACE1BACE2PIM1MAPK1OPRL1 | |
| SCHEMBL171233 | 0.80 | BACE1 (0.46) | BACE1BACE2PTGS1PTGS2PIM1 | |
| SCHEMBL18466257 | 0.77 | FYN (0.42) | BACE1BACE2CNR2NR1H4 | |
| SCHEMBL15830060 | 0.77 | BACE1 (0.48) | BACE1BACE2PTGS1PTGS2PIM1 | |
| SCHEMBL29953228 | 0.77 | BACE1 (0.43) | BACE1BACE2EPHX2PTGS1PTGS2 | |
| SCHEMBL16217349 | 0.74 | CNR2 (0.47) | EPHX2PIM1MAPK1CNR2 | |
| Trifluoroacetic Acid SCHEMBL30279195 | 0.74 | PTGS1 (0.44) | EPHX2PTGS1PTGS2CNR2NR1H4 | |
| SCHEMBL1343010 | 0.74 | MAPK1 (0.43) | BACE1BACE2PTGS1PTGS2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | BACE1 1014/4885BACE2 3037/4885EPHX2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.